Dyno Therapeutics
AI-enabled genetic technology development for biotechnology and medicine developers
Highlights
- New on EvolcAdded 2026-11-13
About Dyno Therapeutics
Dyno Therapeutics develops genetic technologies using machine learning and computational biology, with a focus on gene delivery and next-generation medicine.
The company is based in Watertown, Massachusetts. Its team includes gene therapy, machine learning, computational biology, and operations specialists; an open role is for a senior machine learning engineer.
Product: Genetic technologies for gene delivery and next-generation medicine, developed using AI and computational biology.
Jobs at Dyno Therapeutics
More biotech & pharma companies
Earli
Develops genetic switches that activate in cancer cells for cancer detection and therapeutic applicationsNew on EvolcEmeraldcloudlab
Remotely controlled life science lab letting pharma, biotech and academic teams run wet-lab experiments through softwareNew on EvolcErasca
Clinical-stage precision oncology company developing therapies that target the RAS/MAPK cancer signaling pathwayNew on EvolcEVERY™
Animal-free egg white protein ingredients (OvoPro) made by precision fermentation for food manufacturers and foodserviceNew on EvolcFormation Bio
AI-driven pharmaceutical company acquiring and developing clinical-stage drugs to bring treatments to patients fasterNew on Evolc
Website technologies
Tools and platforms detected on this company’s website, grouped by purpose. Dates record when Evolc observed them.
Content delivery
- CloudflareHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Response headerserver
- Response headerserver
- Response headerserver
Content management
- WebflowHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
Hosting
- AWSHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
Website detection does not establish a paid subscription or company-wide use. Tools loaded after consent or sign-in may be missed. “No longer observed” does not prove the company stopped using a tool.